Superpower costs $499 a year for a 100+ biomarker membership with two draws included — the same price and substantially the same structure as Function Health. The measurable difference between them is the app experience, not the price.
That makes the worth-it question unusual. It is rarely a choice between this and nothing. It is a choice between this and a near-identical product, and then a much larger question about whether a data-only platform is the right category at all.
Public litigation
Superpower Health is the defendant in an open federal lawsuit brought by Function Health alleging false advertising and unfair competition under the Lanham Act (C.D. Cal., filed January 2026). These are allegations, not findings — Justia docket 2:26-cv-00810. Nothing in the case has been decided, and the claims concern advertising and competition rather than laboratory quality or the contents of the panel. The practical implication for a buyer is narrow: treat superiority claims from either company as unverified marketing, and compare the published marker lists directly instead.
The cost math
Priced against every other route to the same information, plus the route to the thing a data platform cannot do.
| Route to the same information | Cost |
|---|---|
| Superpower membership | $499/yr, 2 draws included |
| Realistic year one with one add-on and one consult | $750–$1,200 |
| Function Health membership (same price band, same structure) | $499/yr |
| InsideTracker single test | $249–$589, no membership |
| Equivalent 100+ marker set ordered a la carte | $1,200–$2,500 |
| Insurance-billed panel through your own physician | $0–$200 copay, typically 10–20 markers |
| Adding a clinician and a prescription pathway (Lifeforce or Opt Health) | $1,900–$3,000/yr |
| Prescription medication, if labs indicate one | Not available here — separate relationship |
On breadth per dollar the membership is competitive: an equivalent 100+ marker set ordered a la carte runs $1,200–$2,500, because advanced markers such as ApoB, Lp(a), and a full thyroid and hormone set are priced individually. The two included draws are what carry the value — a single snapshot elsewhere costs more than a year of membership here.
Against InsideTracker the break-even is roughly one and a half tests a year. Below that, pay-per-test is cheaper; above it, a membership that bundles two draws is, and it carries about twice the markers.
Against the prescribing tier, the comparison is not about efficiency. A clinician and a prescription pathway cost roughly four times what data alone costs, whichever way you assemble them — and if treatment is what you actually need, buying data first and treatment second usually costs more than buying them together.
Insurance does not cover the membership, so pre-tax dollars are the only mechanism that changes the effective price. Our Superpower cost breakdown covers how HSA and FSA funds apply to a bundled membership fee and what documentation plan administrators tend to require. Confirm with your own plan administrator before assuming the full amount qualifies.
When Superpower is worth it
- You have never done a broad panel and you know a clinical dashboard would lose you. The guided onboarding and plain-language framing are built for exactly this reader. A panel you actually engage with outperforms a wider one you open once.
- You want prompts that push you toward acting. The action layer nudges you on flagged results rather than presenting numbers and stopping. If your failure mode is having data and doing nothing, that is a real feature.
- You will use both included draws. The value here compounds across draws — the second one is where a trend line starts existing. Members who book both get roughly twice the product for the same $499.
- You want a broad baseline before deciding anything bigger. Running a $499 panel first is an efficient way to establish whether you need a prescribing-tier program at all, at a sixth of the cost of finding out the expensive way.
When Superpower is not worth it
- You already use Function Health. The base panels overlap heavily and the pricing is identical. Switching buys a different presentation of largely the same measurements, not new information.
- You want a physician. Live consults are $150–$300 add-ons rather than an included relationship. If ongoing clinician contact is what you want, Lifeforce at ~$1,900/yr or Opt Health at ~$3,000/yr include it rather than metering it. Our Lifeforce vs Function Health comparison sets out what that upgrade buys, and it reads across directly, since Function Health is priced and structured the same way Superpower is.
- You want prescriptions based on your labs. This platform does not prescribe. For conventional TRT, Hone Health at $45–$220 a month is the cheaper entry; for broader protocols, the physician-led tier is the category.
- You will test once and stop. A membership priced around two draws is inefficient if you use one. InsideTracker sells a one-time entry-tier test at ~$249 with nothing to cancel.
What would change the answer
- Symptoms appearing. Fatigue, sleep disruption, weight change, or low libido move the question from screening to diagnosis. Measurement alone stops being enough, and a platform that can prescribe becomes the better spend.
- A flagged marker. One off-range result changes what you are buying. You are now retesting on a schedule and probably want a clinician reading it, which shifts the comparison toward bundled programs.
- Turning 40. The base rate of actionable findings rises materially through the forties across hormonal, metabolic, and cardiovascular markers. A panel that was a baseline exercise at 32 is a screening exercise at 45.
- Losing the person who reads it with you. Written commentary flags what is off-range; it does not tell you what to do. If your physician or coach leaves the picture, a data-only membership loses much of its point until you replace them.
What members most often regret
Reactive add-on buying. Advanced panels and consults appear in the app at the moment results land — precisely when a flagged marker makes an upsell feel necessary rather than optional. That is effective product design and it is how a $499 membership becomes a $1,200 year. Decide before your first draw which add-ons you would buy and at what threshold.
The unbooked second draw. The most expensive mistake available here is paying for two draws and using one. It converts a longitudinal product into an expensive snapshot and halves the value of the membership. Book the second draw the day the first results land.
Data without a destination. A 100+ marker panel reliably surfaces something, and this platform cannot treat it. Members who had no physician, no coach, and no plan for the results describe a report they found interesting and did nothing with. Know who is reading this with you before you pay.
The Verdict
Yes if you want a 100+ marker panel and know a clinical interface would cause you to disengage. Comparable to Function Health if a clinical interface is fine — the panels and pricing are close enough that this is not a price decision. No if you want a physician or a prescription pathway, since neither is included at any tier.
The price is fair for the category and the panel is competitive. The choice between this and its nearest equivalent is a preference decision, not a value one, and anyone framing it as a price comparison is comparing two identical numbers. The larger decision is whether a data-only product is the right category for you at all — which comes down to whether you expect to act on what you find, and whether acting will require someone who can prescribe.
Frequently Asked Questions
Is Superpower worth $499 a year?
For app-first users who want a guided experience alongside a 100+ marker panel, yes — the price matches the category and the two included draws are what make it competitive. For anyone who wants a physician relationship or a prescription pathway, no, because neither is included at any tier.
Is Superpower worth it if I already use Function Health?
Usually not. The base panels overlap heavily, so switching rarely surfaces meaningfully new information. You would be paying $499 for a different presentation of largely the same measurements. The exception is someone who genuinely stopped engaging with the other platform, since an unused membership is worth nothing regardless of panel quality.
Is Superpower worth it for someone who has never had labs?
This is the use case the product is built around. The guided onboarding and plain-language framing make a first 100+ marker report considerably less intimidating than a clinical dashboard, and engagement is what determines whether a biomarker membership produces anything. A panel you understand outperforms a wider panel you ignore.
Is Superpower worth it if I want treatment rather than data?
No. It measures and does not prescribe. For treatment, physician-led programs are the category — Hone Health for conventional TRT, Lifeforce for NP-led mid-tier care, Maximus for fertility-preserving protocols, and Opt Health for physician-led care on a 3–4 month cadence, listed alphabetically by scope rather than ranked.
What do members most often regret?
Reactive add-on buying. Advanced panels and consults are surfaced in the app when results land, which is the moment a flagged marker makes any add-on feel necessary. Members who set their rules before the first draw spent meaningfully less than members who decided in the moment.
Does the app experience actually change outcomes?
It changes engagement, which is the variable that matters most in a product whose value compounds across draws. A membership whose second draw never gets booked delivers a fraction of what it could. Whether better onboarding is worth anything to you depends on whether a clinical interface would have caused you to disengage.
Will a 100+ marker panel find cancer or replace my annual physical?
No. A blood panel measures biochemistry, so it cannot see anything that does not show up in blood. Superpower is a remote, blood-only service that does not examine you, image you, or manage a condition you already carry a diagnosis for, which means a clean report is not reassurance about anything structural. That is a limit of the category rather than a fault of this product, and it is why a panel belongs alongside age-appropriate screening and a physician relationship rather than in place of either.